Insulin glargine 300 U/ml versus insulin degludec 100 U/ml in type 2 diabetic patients treated with basal-bolus insulin therapy

Insulin glargine 300 U/ml versus insulin degludec 100 U/ml in type 2 diabetic patients treated with basal-bolus insulin therapy - Insulin glargine 300 U/ml versus insulin degludec 100 U/ml in type 2 diabetic patients treated with basal-bolus insulin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019969

Enrollment

Registered

2015-12-01

Start date

2015-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

insulin glargine 300 U/ml (dose-adjustment period + 5-week blood glucose-assessment period) at the first term and insulin degludec 100 U/ml (dose-adjustment period + 5-week blood glucose-assessment pe

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - adults with type 2 diabetes mellitus - patients treated with basal-bolus insulin therapy - patients with regular lifestyle. - patients whose time interval between breakfast and lunch, lunch and dinner, and dinner and breakfast are 6, 6, and 12 hours, respectively, with a tolerance of +/- 3 hours.

Exclusion criteria

Exclusion criteria: - treated with anti-diabetic agents other than insulin - difficult to perform self-monitoring of blood glucose - severe hepatic, renal and/or cardiac disease - hypersensitivity to insulin degludec and/or insulin glargine - pregnant or breast-feeding females. - Patients who are judged by the investigator to be inappropriate for this study for any other reason.

Design outcomes

Primary

Measure	Time frame
daily profiles of glucose levels	—

Countries

Japan

Contacts

Public ContactToshihiko Shiraiwa

Shiraiwa Medical Clinic Shiraiwa Medical Clinic

shiraiwa@endmet.med.osaka-u.ac.jp072-971-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026